Clinical trials
Targeted Therapy clinical trials
Below are recruiting targeted therapy clinical trials, each written for real people, not researchers. We’re tracking 309 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06653517RecruitingPhase 2
Targeted therapy before surgery for a type of jaw tumor
This trial tests whether taking two targeted drugs (dabrafenib and trametinib) before surgery can shrink a specific type of jaw tumor called ameloblastoma. The tumor must have a certain genetic change (BRAF V600E mutation) and require a large jaw surgery. The goal is to see if the drugs make surgery less extensive or more successful.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06679634RecruitingPhase 2
Topotecan eye patch for retinoblastoma
This trial tests a new way to deliver the chemotherapy drug topotecan directly to the eye (via a small patch placed on the eye surface) for children with retinoblastoma that either needs eye removal or has come back after standard treatment. It aims to see if this approach can help save the eye and vision.
New York, New YorkAges Up to 8 years - NCT06691061Recruiting
Comparing advanced treatments for ulcerative colitis after anti-TNF therapy
This trial compares three types of medications (vedolizumab, ustekinumab, and JAK inhibitors) in people with ulcerative colitis who have already tried an anti-TNF drug but still have active disease. The goal is to see which treatment works best as a second option.
Mialn, ItalyAges 18 years+ - NCT06718257Recruiting
Chemo with immunotherapy and targeted drugs for bile duct cancer
This trial tests whether adding immunotherapy and targeted therapy to standard chemotherapy can help treat intrahepatic cholangiocarcinoma (a type of bile duct cancer). It is for patients who are starting treatment with one of two specific chemo regimens, possibly combined with the new drugs.
Hangzhou, ZhejiangAges 18 years+ - NCT06742021Recruiting
MRI test to predict immune therapy response in lung cancer
This trial uses a special MRI technique (4D FreeBreathing) to see if it can predict how well immune therapy or targeted therapy works for your lung cancer. It may help doctors choose the best treatment for you more quickly.
Kunming, YunnanAges 18–75 - NCT06771960Recruiting
Targeted therapy before surgery for EGFR lung cancer
This trial looks at how well a targeted therapy works before surgery for people with EGFR-mutated non-small cell lung cancer. It aims to understand the link between a heart rhythm measure (RVT) and patient outcomes.
Guangzhou, GuangdongAges 18–80 - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new drug to standard care for prostate cancer
This trial tests a new study drug (AAA817) against the usual treatments for men with a certain type of advanced prostate cancer that has spread and is no longer responding to a targeted radiation therapy (177Lu-PSMA). The goal is to see if the new drug can help control the disease longer.
Los Angeles, CaliforniaAges 18–100 - NCT06781905Recruiting
Brain effects of ALK/ROS1 lung cancer drugs and quality of life
This study looks at how certain targeted therapy drugs for ALK/ROS1-positive lung cancer may affect thinking, memory, mood, and mental health. It aims to build a special care and research path where patients and researchers work together to understand and manage these side effects.
BronAges 18 years+ - NCT06793189RecruitingPhase 2
Risk-Adapted Targeted Therapy for Untreated MZL
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
Shanghai, ChinaAges 18 years+ - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+ - NCT06865105RecruitingPhase 2
Targeted treatments for active psoriatic arthritis
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
Huntington Beach, CaliforniaAges 18 years+ - NCT06920433RecruitingEarly Phase 1
Targeted cell therapy for tough lupus with kidney involvement
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06939166RecruitingEarly Phase 1
Immune cell therapy for relapsed neurological autoimmune diseases
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT07164560RecruitingPhase 1
CAR-NK cell therapy for relapsed T-cell lymphoma
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT07180927RecruitingPhase 1/Phase 2
DLL3 car-t therapy for recurrent brain tumors
This trial tests a new immune therapy called DLL3 CAR-T cells for people with brain tumors that have come back or not responded to treatment. It aims to see if these specially designed cells can attack the tumor safely.
Shenzhen, GuangdongAges 2–70 - NCT07191730Recruiting
Heart risk prediction for cancer patients on certain chemotherapies
This trial uses a special scoring system (ML Score) to predict if you might develop heart problems while receiving anthracycline chemotherapy or HER2-targeted therapies. It helps doctors decide on the best heart monitoring plan before starting treatment.
CaenAges 18 years+ - NCT07081646RecruitingPhase 1/Phase 2
CAR T cell therapy for AL amyloidosis
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
Phoenix, ArizonaAges 18 years+ - NCT07305116RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
Hangzhou, ZhejiangAges 3 years+ - NCT07309718Recruiting
Stroke Risk Assessment for Brain Artery Narrowing
This study looks at a new way to measure stroke risk in people with a specific type of brain artery narrowing (atherosclerosis) in the front part of the brain. You might participate if you have this condition and are willing to have imaging tests and take standard medicines.
Beijing, Xicheng DistrictAges 18–80 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07347951RecruitingPhase 2
New drug combo for rectal cancer patients who want to save their anus
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
Wenzhou, ZhejiangAges 18–75 - NCT07350837RecruitingEarly Phase 1
CAR-T therapy for highly sensitized kidney transplant patients
This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.
Wuhan, HubeiAges 18–65 - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+
Hear when a new Targeted Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for targeted therapy?
- Yes. Clin2 currently lists 309 recruiting targeted therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a targeted therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a targeted therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.